Sabrina Serani

New York

Senior Editor at Targeted Oncology

Senior Editor at MJH Life Sciences

Featured in: Favicon

bobvila.com Favicon

starnewsgroup.com Favicon

mjhlifesciences.com Favicon

targetedonc.com Favicon

newsbreak.com Favicon

ajmc.com

cancernetwork.com Favicon

curetoday.com Favicon

onclive.com Favicon

managedhealthcareexecutive.com + 2 more

Articles

Nivolumab Improves Outcomes in Esophageal/GEJ Cancer

1 week ago | targetedonc.com | Sabrina Serani

After 5 years of follow-up, adjuvant nivolumab (Opdivo) continued to demonstrate sustained benefits in disease-free survival (DFS) and distant metastasis-free survival (DMFS) in patients with resected esophageal cancer (EC) or gastroesophageal junction cancer (GEJC) following neoadjuvant chemoradiotherapy (CRT), according to results from the phase 3 CheckMate 577 trial (NCT02743494).
Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

1 week ago | oncnursingnews.com | Sabrina Serani

The FDA has granted EBC-129, a novel antibody-drug conjugate (ADC), fast track designation for use in pancreatic ductal adenocarcinoma, according to a news release from The Experimental Drug Development Centre in Singapore.1 The fast track designation facilitates the expedited development of EBC-129, allowing for more frequent discussion with the FDA as well as providing potential eligibility for priority review and accelerated approval, as well as rolling review of any future biologic...
FDA Fast-Tracks Novel ADC in Pancreatic Cancer

1 week ago | targetedonc.com | Sabrina Serani

The FDA has granted fast track designation to EBC-129 for the treatment of pancreatic ductal adenocarcinoma (PDAC). EBC-129 is a novel antibody-drug conjugate (ADC). Updated data from the phase 1 study (NCT05701527) evaluating EBC-129 will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC

1 week ago | targetedonc.com | Sabrina Serani

The FDA has granted priority review to sevabertinib (BAY 2927088) for the treatment of advanced HER2-mutant non–small cell lung cancer (NSCLC). This designation is supported by the ongoing phase 1/2 SOHO-01 study (NCT05099172). Data from SOHO-01 showed an objective response rate (ORR) of 70.5% in patients with pretreated disease.
Triplet Therapy Shows Promise in High-Risk Relapsed CLL

1 week ago | targetedonc.com | Sabrina Serani

The measurable residual disease (MRD)-guided triplet combination of zanubrutinib (Brukinsa), venetoclax (Venclexta), and obinutuzumab (Gazvya) led to deep remissions in patients with relapsed chronic lymphocytic leukemia (CLL), especially in a population enriched with high-risk genetics and previous exposure to Bruton tyrosine kinase inhibitors (BTKis) and venetoclax, according to findings from the phase 2 CLL-BZAG trial (NCT04515238).1The final efficacy analysis included 40 patients.
EFTISARC-NEO Trial Meets Primary End Point in Soft Tissue Sarcoma

1 week ago | targetedonc.com | Sabrina Serani

The phase 2 EFTISARC-NEO trial (NCT06128863) evaluating eftilagimod alfa (IMP321) with radiotherapy plus pembrolizumab (Keytruda) as neoadjuvant therapy for resectable soft tissue sarcoma met its primary end point of tumor hyalinization/fibrosis, an early surrogate end point associated with improved overall survival (OS) and recurrence-free survival (RFS).1 “It is very encouraging to see the chemotherapy-free combination with efti[lagimod alfa] far exceed the ambitious target we initially set...
Sacituzumab Govitecan Improves PFS in Metastatic TNBC

1 week ago | targetedonc.com | Sabrina Serani

The phase 3 ASCENT-03 study (NCT05382299) evaluating sacituzumab govitecan-hziy (Trodelvy) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) not eligible for PD-(L)1 inhibition met its primary end point of progression-free survival (PFS).1The antibody-drug conjugate sacituzumab govitecan led to a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy, and the safety profile of the agent was consistent with prior studies.
Novel CRS Prevention Therapy Granted FDA Orphan Drug Designation

1 week ago | targetedonc.com | Sabrina Serani

The FDA has granted orphan drug designation (ODD) to POLB 001. POLB 001 is an oral preventative therapy for bispecific T-cell engager (BiTE) therapy-induced cytokine release syndrome (CRS). The first patient is expected to be dosed with POLB 001 in a phase 2a study this year. POLB 001, a preventative therapy for CRS caused by BiTE therapy, has been granted ODD by the FDA.1ODD is intended to support the development of agents for rare disorders that affect less than 200,000 patients in the US.
Younger Adults See Rising Pancreatic & Colorectal Cancer Rates

1 week ago | targetedonc.com | Sabrina Serani

May 26, 2025Fact checked by In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients. Clinicians have been seeing rising rates of cancers, specifically pancreatic and colorectal cancers, in younger patients in the past 10 years.
Statins Linked to Improved Survival in Patients With CLL/SLL

2 weeks ago | targetedonc.com | Sabrina Serani

In the first large-scale analysis to specifically investigate the use of statins in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), researchers identified that the use of statins was associated with improved overall survival and cancer-specific survival, regardless of patient demographics.